Search research articles
Contact Us
Filters
Showing results (91-100 of 107) with videos related to
Page
of 11
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 6, 2025
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief Report
Gregory J Riely, Myung-Ju Ahn, Jeffrey M Clarke, et al.
The Journal of Clinical Investigation
|
July 17, 2019
The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis
Karthik Suresh, Jarushka Naidoo, Qiong Zhong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 15, 2024
Divergent Clinical and Immunologic Outcomes Based on STK11 Co-mutation Status in Resectable KRAS-Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade
Samuel Rosner, Sydney Connor, Khaled Sanber, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 22, 2025
Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis
Adam Barsouk, Omar Elghawy, Alex Watts, et al.
Biorxiv : the Preprint Server for Biology
|
July 10, 2023
Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer
Joseph C Murray, Lavanya Sivapalan, Karlijn Hummelink, et al.
Nature Medicine
|
March 20, 2024
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses
Ronan J Kelly, Blair V Landon, Ali H Zaidi, et al.
Journal of the American Society of Nephrology : JASN
|
January 4, 2020
Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study
Frank B Cortazar, Zoe A Kibbelaar, Ilya G Glezerman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 23, 2019
Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer
Jiajia Zhang, Zhicheng Ji, Justina X Caushi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 8, 2023
Elucidating the Heterogeneity of Immunotherapy Response and Immune-Related Toxicities by Longitudinal ctDNA and Immune Cell Compartment Tracking in Lung Cancer
Joseph C Murray, Lavanya Sivapalan, Karlijn Hummelink, et al.
Oncology (Williston Park, N.Y.)
|
April 27, 2023
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma
Daniel Vt Catenacci, Yoon-Koo Kang, Hope E Uronis, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 107) with videos related to
Sort By:
Page
of 11
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 6, 2025
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief Report
Gregory J Riely, Myung-Ju Ahn, Jeffrey M Clarke, et al.
The Journal of Clinical Investigation
|
July 17, 2019
The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis
Karthik Suresh, Jarushka Naidoo, Qiong Zhong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 15, 2024
Divergent Clinical and Immunologic Outcomes Based on STK11 Co-mutation Status in Resectable KRAS-Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade
Samuel Rosner, Sydney Connor, Khaled Sanber, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 22, 2025
Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis
Adam Barsouk, Omar Elghawy, Alex Watts, et al.
Biorxiv : the Preprint Server for Biology
|
July 10, 2023
Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer
Joseph C Murray, Lavanya Sivapalan, Karlijn Hummelink, et al.
Nature Medicine
|
March 20, 2024
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses
Ronan J Kelly, Blair V Landon, Ali H Zaidi, et al.
Journal of the American Society of Nephrology : JASN
|
January 4, 2020
Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study
Frank B Cortazar, Zoe A Kibbelaar, Ilya G Glezerman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 23, 2019
Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer
Jiajia Zhang, Zhicheng Ji, Justina X Caushi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 8, 2023
Elucidating the Heterogeneity of Immunotherapy Response and Immune-Related Toxicities by Longitudinal ctDNA and Immune Cell Compartment Tracking in Lung Cancer
Joseph C Murray, Lavanya Sivapalan, Karlijn Hummelink, et al.
Oncology (Williston Park, N.Y.)
|
April 27, 2023
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma
Daniel Vt Catenacci, Yoon-Koo Kang, Hope E Uronis, et al.
Page
of 11